MPN

JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for patients with polycythemia vera.

Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.

An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an expert.

Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis.

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.

One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment that remains strong despite some setbacks.

While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia.

A patient with MPN urges others to ask questions about treatment options, which may also include inquiring about clinical trials.

A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.

An MPN advocate used his personal experiences to inform his dedication to patient-centered research and support programs for patients.

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on research and treatment development.

A health care professional talks about the importance of a supportive care team, especially since every patient with MPNs presents differently.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Adding pelabresib to a JAK inhibitor may improve multiple aspects of myelofibrosis, including spleen size, symptoms and bone marrow fibrosis.

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.

CURE celebrated seven MPN Heroes, who ranged from patients to medical professionals, on the contributions they made in the community.

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, research showed.

Second-line treatment with Inrebic has been shown to be beneficial for patients with myelofibrosis previously treated with Jakafi.

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.

Keri is also a true partner in the management and care of the whole patient.

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.

The development of new or worsening anemia did not decrease Jakafi’s efficacy in treating primary or secondary myelofibrosis.